Cargando…

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study

OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18–80 years) wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wissel, Jörg, Bensmail, Djamel, Ferreira, Joaquim J., Molteni, Franco, Satkunam, Lalith, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, Flatau-Baqué, Birgit, Simon, Olivier, Rochford, Edward T.J., Dressler, Dirk, Simpson, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379931/ https://www.ncbi.nlm.nih.gov/pubmed/28283596 http://dx.doi.org/10.1212/WNL.0000000000003789

Ejemplares similares

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Wissel, Jörg, et al.
Publicado: (2021)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Albanese, Alberto, et al.
Publicado: (2023)

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
por: Ianieri, Giancarlo, et al.
Publicado: (2018)

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
por: Berweck, Steffen, et al.
Publicado: (2022)

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
por: Kaňovský, Petr, et al.
Publicado: (2021)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability
por: León-Valenzuela, Angel, et al.
Publicado: (2020)

Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study
por: Dressler, Dirk, et al.
Publicado: (2015)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study
por: Jog, Mandar, et al.
Publicado: (2020)

IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study(1)
por: Heinen, Florian, et al.
Publicado: (2021)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis
por: Bonfert, Michaela, et al.
Publicado: (2023)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020)

Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy
por: Kaňovský, Petr, et al.
Publicado: (2022)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
por: de Sanctis Pecora, Carla
Publicado: (2020)

IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
por: Hosseini, Meghdad, et al.
Publicado: (2023)

IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
por: Marciniak, Christina, et al.
Publicado: (2018)

IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study
por: Pavicic, Tatjana, et al.
Publicado: (2015)

IncobotulinumtoxinA Injection for Treating Children with Idiopathic Toe Walking: A Retrospective Efficacy and Safety Study
por: Filippetti, Mirko, et al.
Publicado: (2022)

IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series
por: da Cunha, Ana Lucia Gonzaga, et al.
Publicado: (2023)

Treatment of Vestibulodynia with Submucosal Injections of IncobotulinumtoxinA into Targeted Painful Points: An Open-Label Exploratory Study
por: Villa-Muñoz, Paula, et al.
Publicado: (2023)

Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE)
por: Masakado, Yoshihisa, et al.
Publicado: (2020)

Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns
por: Rahimi, Fariborz, et al.
Publicado: (2015)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gr3naci0134omounvuqr0865k5